Arbutus Biopharma Corporation $ABUS Shares Sold by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP reduced its holdings in Arbutus Biopharma Corporation (NASDAQ:ABUS) by 17.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 800,000 shares of the biopharmaceutical company’s stock after selling 165,000 shares during the period. Hudson Bay Capital Management LP owned approximately 0.42% of Arbutus Biopharma worth $3,632,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of ABUS. Goldman Sachs Group Inc. raised its holdings in Arbutus Biopharma by 290.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,075,948 shares of the biopharmaceutical company’s stock valued at $7,245,000 after acquiring an additional 1,544,070 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Arbutus Biopharma by 63.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,575,941 shares of the biopharmaceutical company’s stock worth $7,960,000 after purchasing an additional 1,000,000 shares during the last quarter. Two Seas Capital LP boosted its holdings in shares of Arbutus Biopharma by 10.3% during the 2nd quarter. Two Seas Capital LP now owns 10,443,317 shares of the biopharmaceutical company’s stock worth $32,270,000 after purchasing an additional 977,361 shares during the last quarter. Bank of America Corp DE grew its position in shares of Arbutus Biopharma by 161.4% in the second quarter. Bank of America Corp DE now owns 1,197,655 shares of the biopharmaceutical company’s stock valued at $3,701,000 after purchasing an additional 739,429 shares in the last quarter. Finally, UBS Group AG grew its position in shares of Arbutus Biopharma by 307.2% in the third quarter. UBS Group AG now owns 774,594 shares of the biopharmaceutical company’s stock valued at $3,517,000 after purchasing an additional 584,386 shares in the last quarter. Hedge funds and other institutional investors own 43.79% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arbutus Biopharma in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Arbutus Biopharma has a consensus rating of “Hold” and a consensus target price of $5.00.

Arbutus Biopharma Price Performance

NASDAQ ABUS opened at $4.24 on Friday. The stock has a market capitalization of $815.44 million, a P/E ratio of -18.43 and a beta of 0.69. The firm’s 50-day moving average is $4.31 and its two-hundred day moving average is $4.43. Arbutus Biopharma Corporation has a 12 month low of $2.70 and a 12 month high of $5.10.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.